Vogt-Koyanagi-Harada disease: Clinical outcomes

Irina Bykhovskaya, Jennifer E. Thorne, John H. Kempen, James P. Dunn, Douglas A. Jabs

Research output: Contribution to journalArticlepeer-review

73 Scopus citations


• PURPOSE: To evaluate the effect of treatment on the incidence of vision impairment and structural ocular complications among patients with Vogt-Koyanagi-Harada (VKH) disease. • DESIGN: Retrospective cohort study. • METHODS: setting: Single-center academic practice. study population: Twenty-four consecutive patients with VKH disease who were referred for evaluation and treatment from November 1984 through May 2004. procedures: Information on patients with VKH disease was entered retrospectively into a database and analyzed with time-dependent techniques. main outcome measures: Incidence of visual impairment and of structural ocular complications. • RESULTS: In better-seeing eyes, the frequencies of vision loss to 20/50 or worse and to 20/200 or worse at presentation were 50% and 30%, respectively. The incidence rates on follow-up examination for vision loss to 20/50 or worse and to 20/200 or worse were 9% per person-year and 7% per person-year in the better-seeing eye. Oral corticosteroid therapy was associated with a reduced risk of loss of visual acuity to the 20/200 or worse in the better-seeing eye (relative risk [RR] = 0.33; P = .05). The use of immunosuppressive drug therapy was associated with a reduced risk of vision loss to the 20/50 or worse and to the 20/200 or worse thresholds in the better-seeing eye (RR = 0.33; P = .05; and RR = 0.08; P = .04, respectively). • CONCLUSION: VKH disease may result in substantial visual impairment. The use of oral corticosteroid or immunosuppressive drug therapy may reduce the risk of vision loss during the follow-up period.

Original languageEnglish (US)
Pages (from-to)674.e1-674.e6
JournalAmerican journal of ophthalmology
Issue number4
StatePublished - Oct 2005

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Vogt-Koyanagi-Harada disease: Clinical outcomes'. Together they form a unique fingerprint.

Cite this